OBSV - ObsEva shares rise amid bullish prospects for women's reproductive health company

Shares of women's reproductive health company ObsEva SA (OBSV) are up 9.2% to $4.33 in morning trading.An article published in TipRanks yesterday listed Switzerland-based ObsEva as one of two stocks that could rally more than 100%.Author Michael Marcus wrote that the company's lead candidate, Yselty, also known as linzagolix, to treat heavy menstrual bleeding associated with uterine fibroids, had positive results in 2 completed phase 3 trials.ObsEva plans to file for an NDA for Yselty in the second quarter of the year.Last month, the European Medicines Agency validated for review a Marketing Authorization Application for Yselty with the company eyeing a potential Q4 2021 approval.Yselty is also under investigation in phase 2 for endometriosis with a phase 3 primary endpoint readout expected in Q4.ObsEva also has ebopiprant in phase 2 for preterm labor with a phase 2b dose ranging study expected to begin in the E.U. and Asia in Q4.

For further details see:

ObsEva shares rise amid bullish prospects for women's reproductive health company